USA – Visby Medical, a San Jose, CA-based medical diagnostic company, expanded its Series E financing to include an additional $35m for a total of over $135m raised in the round.
The additional investment was led by Lightrock, who joined existing Series E investors including John Doerr, Cedars Sinai Medical Center, ND Capital, Artiman Ventures, Pitango Venture Capital, Blue Water Life Science Advisors and J Ventures. The additional investment will be used to enable the company to scale production capacity, further expand the product menu to include advanced respiratory health tests, antimicrobial resistance panels, and deliver the power of PCR diagnostics to consumers at-home.Led by Founder and CEO Adam de la Zerda, PhD., Visby Medical is advancing patented gold standard PCR diagnostic technology in multiple therapeutic areas. The FDA-cleared Visby Medical Sexual Health Click Test is already being used in U.S. CLIA-waived settings, such as Urgent Care and women’s health clinics, to detect gonorrhea, chlamydia and trichomonas via self-collected vaginal swabs and deliver results in less than 30 minutes, eliminating the need for presumptive treatment.The Visby Medical technology is also helping to fight the global pandemic via the Visby Medical COVID-19 Test, and its pipeline includes tests for other infectious diseases. The company is accelerating the delivery of fast and accurate, palm-sized PCR diagnostics to the point of care, and eventually for use at home.29/06/2022
